SLRN Stock Overview
A clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Acelyrin, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.78 |
| 52 Week High | US$29.33 |
| 52 Week Low | US$3.36 |
| Beta | 0 |
| 11 Month Change | -13.17% |
| 3 Month Change | 16.59% |
| 1 Year Change | -82.37% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -79.66% |
Recent News & Updates
Shareholder Returns
| SLRN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.2% | 0.1% | 0.07% |
| 1Y | -82.4% | 14.0% | 22.7% |
Return vs Industry: SLRN underperformed the US Biotechs industry which returned 14% over the past year.
Return vs Market: SLRN underperformed the US Market which returned 22.7% over the past year.
Price Volatility
| SLRN volatility | |
|---|---|
| SLRN Average Weekly Movement | 12.8% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SLRN's share price has been volatile over the past 3 months.
Volatility Over Time: SLRN's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 93 | Mina Kim | www.acelyrin.com |
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company’s lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease.
Acelyrin, Inc. Fundamentals Summary
| SLRN fundamental statistics | |
|---|---|
| Market cap | US$477.08m |
| Earnings (TTM) | -US$299.80m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.6x
P/E RatioIs SLRN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SLRN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$299.80m |
| Earnings | -US$299.80m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.00 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SLRN perform over the long term?
See historical performance and comparison